Luvixasertib (hydrochloride) (Standard)

Luvixasertib (hydrochloride) (Standard) is the analytical standard of Luvixasertib (hydrochloride) (HY-101340A) . This product is intended for research and analytical applications. CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

Product Specifications

CAS Number

[1610677-37-6]

Target

Mps1; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Others

Field of Research

Cancer

Smiles

CC1=CC(C2=C3N=C(OC4=CN=CC=C4)C=C(NC[C@@H]5C[C@@](O)(C)C5)N3N=C2)=CC=C1C(NC6CC6)=O.Cl

Molecular Formula

C28H31ClN6O3

Molecular Weight

535.04

References & Citations

[1]Liu Y, et al. Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent. ACS Med Chem Lett. 2016 May 6;7 (7) :671-5.|[2]Mason JM, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114 (12) :3127-3132.